论文部分内容阅读
目的 :观察布地奈德吸入联合喘可治注射液辅助治疗慢性阻塞性肺疾病急性加重期的临床疗效。方法 :选取2015年9月~2016年9月我院收治的128例患者为研究对象,随机抽取64例纳入对照组,给予常规治疗,另64例纳入研究组,给予布地奈德吸入联合喘可治注射液辅助治疗,对比两组患者治疗效果。结果 :研究组的治疗总有效率高于对照组,差异显著;研究组的临床症状积分、FEV1、C反应蛋白、白细胞均优于对照组,差异显著。结论 :布地奈德吸入联合喘可治注射液辅助治疗慢性阻塞性肺疾病急性加重期患者,疗效确切,值得推广。
Objective: To observe the clinical efficacy of budesonide inhalation combined with chuankezhi injection in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods: A total of 128 patients admitted to our hospital from September 2015 to September 2016 were selected and randomly divided into control group (64 cases), conventional therapy (64 cases) and budesonide inhalation combined with asthma Treatment of adjuvant therapy injection, compared two groups of patients treatment effect. Results: The total effective rate of the treatment group was higher than that of the control group, and the difference was significant. The clinical symptom scores, FEV1, C-reactive protein and white blood cells in the study group were all better than those in the control group. Conclusion: Budesonide inhalation combined with Chuankezhi injection in the treatment of acute exacerbation of chronic obstructive pulmonary disease patients, the exact effect, it is worth promoting.